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immunodeﬁciency virus (HIV)-1 genital shedding. Whether HSV-2 shedding contributes to the selection of speciﬁc genital HIV-1 variants
remains unknown. We evaluated the genetic diversity of genital and blood HIV-1 RNA and DNA in 14 HIV-1/HSV-2-co-infected women,
including seven with HSV-2 genital reactivation, and seven without as controls. HIV-1 DNA and HIV-1 RNA env V1–V3 sequences in
paired blood and genital samples were compared. The HSV-2 selection pressure on HIV was estimated according to the number of
synonymous substitutions (dS), the number of non-synonymous substitutions (dN) and the dS/dN ratio within HIV quasi-species. HIV-1
RNA levels in cervicovaginal secretions were higher in women with HSV-2 replication than in controls (p0.02). Plasma HIV-1 RNA and
genital HIV-1 RNA and DNA were genetically compartmentalized. No differences in dS, dN and the dS/dN ratio were observed between
the study groups for either genital HIV-1 RNA or plasma HIV-1 RNA. In contrast, dS and dN in genital HIV-1 DNA were signiﬁcantly
higher in patients with HSV-2 genital reactivation (p <0.01 and p <0.05, respectively). The mean of the dS/dN ratio in genital HIV-1 DNA
was slightly higher in patients with HSV-2 genital replication, indicating a trend for purifying selection (p 0.056). HSV-2 increased the
genetic diversity of genital HIV-1 DNA. These observations conﬁrm molecular interactions between HSV-2 and HIV-1 at the genital tract level.
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of the article.Clinical Microbiology and Infection © 2015 European Society of CIntroductionThe female genital tract constitutes an anatomical human im-
munodeﬁciency virus (HIV)-1 reservoir, in which there is active
production of both cell-free HIV RNA and cell-associated HIV-Clin Microbiol Infect 2015; 21: 873.e1–873.e9
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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mission [2]. The cervicovaginal production of HIV is considered
to be partly compartmentalized, at least transiently, in com-
parison with the virus population that replicates within the
systemic compartment [3–7], and may be inﬂuenced by
numerous local and systemic factors, notably the presence of
other sexually transmitted infections and mucosal inﬂammation
[1,6,8]. In particular, herpes simplex virus type 2 (HSV-2) may
increase the infectiousness of HIV-1-infected individuals by
increasing the frequency and quantity of HIV-1 genital shedding
during clinical and subclinical herpetic episodes [9–13].
Both the quantity of HIV-1 in the genital tract and its di-
versity seem to play a role in sexual transmission. The het-
erosexual acquisition of HIV-1 infection is considered to be the
result of selection of HIV-1 genetically restricted variants from
the genital compartment of the HIV-1-infected index partner to
both the genital compartment and systemic compartment of
the newly infected partner [2,14,15].
In addition to its impact on genital HIV-1 replication,
whether HSV-2 genital shedding may participate in the selection
of speciﬁc HIV-1 variants within the female genital reservoir
remains unknown. The aim of the present study was to evaluate
the genetic diversity of HIV-1 cervicovaginal variants during
episodes of HSV-2 genital reactivation in HIV-1/HSV-2-co-
infected women.Materials and methodsParticipant recruitment and sample selection
The ANRS12-12 Study was an individually randomized,
placebo-controlled trial of acyclovir (400 mg three times daily
for 5 days) added to the standard antibiotic combination used
for the syndromic management of genital ulcer disease (GUD).
Trial participants were women presenting with GUD at sexu-
ally transmitted infection (STI) clinics in Accra and Kumasi
(Republic of Ghana) and Bangui (Central African Republic). Full
details of the procedures have been previously described [9,16].
The aetiology of GUD was determined by testing lesional swab
specimens for HSV-2, Haemophilus ducreyi, Treponema pallidum,
Klebsiella granulomatis and Chlamydia trachomatis lymphogranu-
loma venereum with molecular techniques, as previously
described [9]. For this study, the samples were selected from
the subgroup of women who were chronically co-infected with
HIV-1 and HSV-2 as determined by serology, including seven
with lesional (vulva or vagina) specimens and cervicovaginal
secretions positive for HSV-2 DNA (group 1), and seven with
lesional specimens negative for HSV-2 DNA and for other
bacterial GUD aetiologies, and with cervicovaginal secretions
also negative for HSV-2 DNA (group 2). Genital sampling wasClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectcarried out when women were presenting with GUD at STI
clinics. None of the women had ever received any antiretroviral
treatment. Ethical approval was received from the research
ethics committees of the Ministries of Health of Ghana and the
Central African Republic, and the London School of Hygiene &
Tropical Medicine. The ANRS12-12 trial was registered with
the International Clinical Trials Registry (ClinicalTrials.gov
number NCT00158483).
Blood and genital sample collection and laboratory
analyses
At STI clinics, a standardized 60-s cervicovaginal lavage (CVL)
ﬂuid specimen was collected and immediately centrifuged
1,000 g for 15 min, and the cellular pellet and cell-free super-
natants were aliquoted and stored frozen at –80°C until pro-
cessing, as previously described [17].
CVL ﬂuid supernatants were examined visually for the
presence of blood, and tested for traces of haemoglobin with
Hemastix dipsticks (Bayer Diagnostics, Puteaux, France). Sam-
ples containing haemoglobin and/or traces of contaminating
semen, as determined by means of a Y chromosome PCR in
DNA extracted from the cellular pellet of CVL ﬂuid, were
excluded [9]. HIV-1 RNA and HSV-2 DNA detection and
quantiﬁcation were performed in the cell-depleted fraction of
the CVL ﬂuid, and HIV-1 RNA detection and quantiﬁcation
were performed in the plasma by real-time RT-PCR, as previ-
ously described [17]. Viral quantiﬁcation was expressed as
copies/mL of collected sample, with a detection threshold of
250 copies/mL. All viral loads were log10-transformed for
analyses.
PCR ampliﬁcation and cloning of the HIV-1 V1–V3 env
gene
Nucleic acids were extracted from 0.2 mL of plasma and from
0.2 mL of the acellular fraction of CVL ﬂuid with the EasyMag
System (bioMérieux, Marcy l’Etoile, France), according to the
manufacturer’s instructions. In addition, DNA was extracted
from the pellet of centrifuged CVL ﬂuid with the Qiagen DNA
minikit (Qiagen Hamburg, Hilde, Germany). Extracted RNAs
from plasma and cell-free CVL RNA were subjected to one-
tube reverse transcription and further ampliﬁcation by means
of the Superscript one-step RT-PCR kit for long templates
(Invitrogen, Groningen, The Netherlands), with E00 and ES8b
as primers, allowing ampliﬁcation of a region of gp120 including
V1, V2, and V3 [15]. Extracted DNA from CVL pellets was
subjected to the same V1–V3 env PCR. Products of the ﬁrst
PCR were then ampliﬁed by nested PCR with the primers E20
and E115 [15]. Cloning was carried out by means of the TOPO
TA Cloning kit for sequencing (Invitrogen). Plasmids were
extracted with the REAL prep 96 plasmid kit (Qiagenious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 873.e1–873.e9
FIG. 1. Unrooted maximum-likelihood phylogenetic tree derived from
V1–V3 env nucleotide sequences obtained from systemic and genital
human immunodeﬁciency virus (HIV)-1 variants in HIV-1/herpes sim-
plex virus type 2 (HSV-2)-co-infected patients with (group 1: D, F, G, H,
K, L, and R) or without (group 2: A, B, C, E, M, N, and O) HSV-2 genital
CMI LeGoff et al. HIV-1 variability during HSV-2 infection 873.e3
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InHamburg). The insert size was evaluated following digestion of
the plasmid with EcoRI (Invitrogen). Plasmids containing inserts
of the expected size were further sequenced. The different
samples were ampliﬁed on separate days to avoid any cross-
contamination.
Genetic diversity and nucleotide sequence analysis
Nucleotide sequences were analysed and aligned by use of
Sequencher software (Gene Codes Corporation, Ann Arbor,
MI, USA) and then Se-Al software (Andrew Rambaut; http://
tree.bio.ed.ac.uk/software/seal/), by visual inspection and
manual adjustment to reading frame and codons. All nucleotide
sequences after validation (no contamination; no primer se-
quences) were submitted to the European Nucleotide Archive
at GenBankEMBL-EBI, with accession numbers ranging from
HF953354 to HF953983 (630 clones). Consensus nucleotide
sequences obtained from each individual sequence were aligned
to reference sequences, and submitted to the Los Alamos HIV
sequence database for HIV subtype identiﬁcation (http://www.
hiv.lanl.gov/content/sequence/NEWALIGN/align.html#ref)
[18]. Evolutionary analyses were conducted with MEGA5 [19]
by using the maximum-likelihood method based on the
Tamura–Nei model (Fig. 1) [20]. All positions containing gaps
and missing data were eliminated. There were a total of 464
positions in the ﬁnal dataset. A discrete gamma distribution was
used to model evolutionary rate differences among sites (ﬁve
categories (+G, parameter = 0.9137)). The rate-variation model
allowed for some sites to be evolutionarily invariable ((+I),
12.9949% sites). The tree is drawn to scale, with branch lengths
measured in the number of substitutions per site. Bootstrap
tests (200 replicates) are used to test the branching order [21].
To avoid any bias caused by clonal resampling, we removed all
redundant identical clones from subsequent analysis (578 single
clones).
Assessment of the compartmentalization of HIV-1 variants
was performed with the cladistic approach [22], as previously
applied by Poss et al. [23]. Brieﬂy, phylogenetic trees of paired
plasma and genital HIV-1 nucleotide sequences derived from
each woman were constructed by parsimony, with DNApars
from the PHYLIP package [24]. Each sequence was further
recoded as two-state characters according to the compartment
from which it came. The number of evolutionary steps required
to ﬁt these character states to the most parsimonious trees
previously found was estimated with DNApars [24]. Thereactivation. The numbers near nodes indicate the bootstrap values (%)
(200 replicates). Values of >70% are considered to be signiﬁcant; 100%
is indicated by stars; only values on major nodes of >49% were noted.
The scale refers to the distance between sequences. Vertical spaces/line
are for clarity only.
fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 873.e1–873.e9
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estimated from 1000 bootstrap trees inferred from the nucle-
otide sequences with seqboot from the PHYLIP package. To
test whether s was smaller than expected from an equivalent
HIV-1 variant population with no compartmentalization (which
corresponds to the null hypothesis of no compartmentalization
of HIV-1 variants), 109 random phylogenetic trees were
generated, and the calculated mean number of compartment
changes under the null hypothesis, s0, was estimated with the
random trees search option of the software PAUP 3.1
(Phylogenetic Analysis Using Parsimony and other methods)
[25]. Finally, the observed s and calculated s0 distributions were
compared.
Variability was analysed by the use of aligned sequences ac-
cording to open-reading frames and codons among all 578 se-
quences of single clones. Synonymous and non-synonymous
nucleotide p distances (dS and dN, respectively) were calcu-
lated for each quasi-species within each compartment (blood,
vaginal ﬂuid (provirus or free virions)) and each patient, all
within the MEGA program [19]. Intrasample calculations
comprised comparisons of clones from the same time-point or
quasi-species (within a compartment); intersample calculations
comprised comparisons of clones one by one from two
different quasi-species (between two compartments). Standard
error estimate(s) were obtained with a bootstrap procedure
(100 replicates). The distances p, deﬁned as the number of
synonymous or non-synonymous substitutions divided by the
total number of synonymous or non-synonymous sites, wereTABLE 1. Virological data from chronically human immunodeﬁc
infected women with HSV-2 genital replication (group 1) and with
controls
Patient
HIV-1
subtypea
HSV-2 DNA loadb
HIV-1
loadc
CVL Plasm
Group 1 (genital herpetic
reactivation)
D Rec Cpx 2.5 5.5
F CRF11 5.1 6.1
G CRF11 5.7 5.9
H CRF02 5.8 5.2
K CRF02 6.4 5.7
L CRF11 6.1 6.7
Re CRF01 3.5 4.8
Group 2 (controls) A CRF02 Undetectable 5.5
B CRF02 Undetectable 4.8
C CRF11 Undetectable 5.9
E CRF11 Undetectable 5.7
M Rec Cpx Undetectable 5.5
N CRF13 Undetectable 4.6
O Rec Cpx Undetectable 6.7
CVL, cervicovaginal lavage; NA, non-ampliﬁable; Rec Cpx, recombinant complex.
aHIV-1 subtype was assessed by comparison with the Los Alamos HIV sequence database fo
align.html#ref as it was in January 2014).
bHSV-2 DNA load was assessed by real-time RT-PCR, as previously described [21], and expr
cHIV-1 RNA load was assessed by real-time RT-PCR, as previously described [21], and expr
dHIV-1 DNA load was assessed in cell fractions of CVL ﬂuid samples by real-time RT-PCR,
eSequences limited to the V3 region.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectused to measure the relative genetic variation between clones
within the Kumar model [26]. A dS/dN ratio of >1.0 was
considered to indicate purifying selection, whereas a dS/dN
ratio of <1.0 was considered to indicate positive selection.
We assessed whether genetic diversity may be related to a
difference in G-to-A hypermutation by comparing the pro-
portion of hypermutated sequences between group 1 and
group 2 with Hypermut 2.0 (http://www.hiv.lanl.gov/content/
sequence/HYPERMUT/hypermut.html). As a reference
sequence for each patient, we used the consensus of all of the
patients’ clones [27,28]. We also compared the GG/GA ratio
between group 1 and group 2 by the use of DAMBE5 [29].
Statistical analyses
Average genetic distances were compared by use of the non
parametric Mann–Whitney U-test and ANOVA with Prism6.0e
(GraphPad Software, La Jolla, CA, USA). The Pearson test was
used for correlation analysis.ResultsStudy population
A total of 14 HIV-1/HSV-2-co-infected women suffering from
GUD were included (Table 1). Seven patients showed positive
PCR detection of HSV-2 DNA in genital secretions (group 1),
whereas the seven remaining patients were negative for HSV-2
DNA in genital secretions (group 2) and were without anyiency virus (HIV)-1/herpes simplex virus type 2 (HSV-2)-co-
out evidence of HSV-2 genital shedding (group 2), selected as
RNA HIV-1
DNA loadd Number of single clones
a CVL Genital
Plasma
HIV-1 RNA
CVL
HIV-1 RNA
CVL
HIV-1 DNA
4.5 3.0 14 19 11
4.0 2.5 13 7 NA
4.2 2.3 15 13 14
5.2 3.1 13 13 NAe
5.3 2.5 18 14 21
4.2 2.4 14 17 17
4.2 4.0 9 NA 15
3.8 2.2 14 12 17
5.0 2.4 19 18 9
3.8 3.2 11 12 NA
3.5 2.5 25 10 15
3.4 3.2 18 22 19
3.6 1.8 14 22 23
4.0 2.9 21 20 NA
r HIV subtype identiﬁcation (http://www.hiv.lanl.gov/content/sequence/NEWALIGN/
essed as log HSV-2 DNA copies/mL; the threshold of detection is 2.4 log10 copies/mL.
essed as log HIV-1 RNA copies/mL; the threshold of detection is 2.4 log10 copies/mL.
as previously described [21], and expressed as log HIV-1 DNA copies/106 cells.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 873.e1–873.e9
CMI LeGoff et al. HIV-1 variability during HSV-2 infection 873.e5bacterial or viral GUD aetiology. In group 1, 96, 83 and 78
V1–V3 single env clones from plasma HIV-1 RNA, cell-free CVL
HIV-1 RNA, and cell-associated CVL HIV-1 DNA, respectively,
were obtained for genetic analyses. In group 2, 122, 116 and 83
V1–V3 single env clones from plasma HIV-1 RNA, cell-free CVL
HIV-1 RNA, and cell-associated CVL HIV-1 DNA, respectively,
were obtained for genetic analyses. Phylogenetic analyses of
V1–V3 env sequences demonstrated clear separation between
groups of variants from each individual, and therefore lack of
cross-contamination between samples (Fig. 1). The plasma HIV-
1 RNA load and the CVL HIV-1 DNA load did not differ be-
tween group 1 and group 2 (p 0.6 and p 0.7, respectively). CVL
HIV-1 RNA loads were higher in the group with HSV-2 genital
shedding than in controls (4.78 vs. 4.28 log10 copies/mL, p
0.02).
Compartmentalization of HIV-1 RNA and DNA in
blood and the genital tract
Possible compartmentalization of HIV-1 RNA and DNA vari-
ants between plasma and genital secretions was investigated in
patients with genital herpetic reactivation as compared with the
control group, in order to assess the possible involvement of
HSV-2 genital shedding in HIV-1 compartmentalization. Phylo-
genetic trees of HIV-1 RNA and DNA sequences for patients
with and without HSV-2 genital replication are shown in Fig. 2
(patients D and N as representative trees for groups 1 and
group 2, respectively) and in Fig. S1 (all subjects). The cladistic
statistical analysis showed signiﬁcant compartmentalization ofFIG. 2. Characteristics of unrooted
phylogenetic trees derived from plasma
human immunodeﬁciency virus (HIV)-1
RNA (closed circles), cervicovaginal
secretion HIV-1 RNA (open circles) and
cervicovaginal secretion HIV-1 DNA
(open squares) V1–V3 env sequences
obtained from the chronically HIV-1/
herpes simplex virus type 2 (HSV-2)-co-
infected woman D suffering from HSV-2
genital reactivation (group 1), and from
the chronically HIV-1/HSV-2-co-infected
woman N without HSV-2 genital reac-
tivation (group 2, as a control). Gaps
were excluded from alignments, and trees
were computed by use of the PHYLIP
package with the neighbour-joining
method and the Kimura two-parameters
evolutionary model [32]. The scale in-
dicates substitutions per site.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InHIV-1 RNA variants between blood and genital compartments
in all cases and controls (Table 2). Furthermore, among patients
with available genital HIV-1 DNA sequences, both genital HIV-1
DNA and HIV-1 RNA variants were compartmentalized in all
patients, and genital HIV-1 DNA and plasma HIV-1 RNA were
compartmentalized variants in 80% (Table 2). These observa-
tions thus indicate that the compartmentalization of HIV-1
RNA and DNA variants in chronically HIV-1-infected patients
persists during HSV-2 genital replication.
Genetic diversity of HIV-1 RNA and DNA in the genital
compartment during genital herpes reactivation
The p distances as number of non-synonymous substitutions
per potential non-synonymous site (dN), the number of syn-
onymous substitutions at potential synonymous sites (dS) and
the dS/dN ratio were assessed to estimate the selective
pressure for genital HIV-1 RNA, plasma HIV-1 RNA and
genital HIV-1 DNA for each patient (Table S1). No differences
in dS, dN and the dS/dN ratio were observed between the two
study groups for either genital HIV-1 RNA or plasma HIV-1
RNA (Fig. 3; Table S1A,B). In contrast, within the 344-bp
sequences, the mean numbers of synonymous substitutions
(12.22 vs. 3.69) and non-synonymous substitutions (9.61 vs.
4.76) in genital HIV-1 DNA were signiﬁcantly higher in pa-
tients with HSV-1 genital reactivation than in controls
(p 0.0079 and p 0.0476, respectively) (Fig. 3. Table S1C), the
difference in genetic diversity being more pronounced for
synonymous substitutions. Furthermore, the mean of the dS/fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 873.e1–873.e9
TABLE 2. p-Values of the cladistic comparisons between the observed numbers of compartment changes (s) and the calculated
numbers of compartment changes under the null hypothesis of no compartmentalization (s0) of the V1–V3 env nucleotide
sequences from human immunodeﬁciency virus (HIV)-1 variants detected in three compartments (i.e. HIV-1 RNA from plasma,
HIV-1 DNA from cervicovaginal secretions, and HIV-1 RNA from cervicovaginal secretions) from chronically HIV-1/herpes
simplex virus type 2 (HSV-2)-co-infected women with HSV-2 genital replication (group 1) and without evidence of HSV-2
genital shedding (group 2), selected as controls
Group 1 (HSV-2 genital reactivation) Group 2 (controls)
D F G H K L Ra A B C E M N O
Comparison 1
Plasma HIV RNA vs. CVL HIV-1 RNA
<0.001 <0.001 <0.001 <0.001 0.003 <0.001 ND 0.042 0.031 0.030 <0.001 <0.001 <0.001 0.007
Comparison 2
Plasma HIV-1 RNA vs. CVL HIV-1 DNA
<0.001 ND <0.001 ND 0.001 <0.001 0.419 <0.001 <0.001 ND <0.001 0.081 <0.001 ND
Comparison 3
CVL HIV-1 RNA vs. CVL HIV-1 DNA
<0.001 ND <0.001 ND <0.001 <0.001 ND <0.001 <0.001 ND <0.001 <0.001 <0.001 ND
Comparison 4
Plasma HIV-1 RNA vs. CVL HIV-1
RNA vs. CVL HIV-1 DNA
<0.001 ND <0.001 ND <0.001 <0.001 ND <0.001 <0.001 ND <0.001 <0.001 <0.001 ND
CVL, cervicovaginal lavage; ND, not determined.
A p-value of <0.05 is considered to be signiﬁcant; that is, it indicates genetic compartmentalization of the V1–V3 env nucleotide sequences detected within the two compared
compartments, demonstrating that the sequences of a given compartment are more closely related together than to the sequences from another compartment.
aSequences limited to the V3 region.
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with HSV-2 genital replication (1.4554) than in controls
(0.8471), suggesting a trend for purifying selection (p 0.056).
We then examined whether the increased diversity in genital
HIV DNA in the group with HSV-2 reactivation was related to
G-to-A hypermutation. The analysis with Hypermut 2.0
revealed only six hypermutated sequences, with the same
proportions in group 1 (n = 3, 3.8%) and in group 2 (n = 3,
3.6%). In addition, the GG/GA ratio was similar between
group 1 (0.67 ± 0.08) and group 2 (0.65 ± 0.08) (ANOVA; un-
paired t-test, p 0.19), thus not supporting increased genetic
diversity in genital HIV DNA related to G-to-A
hypermutation.
No correlations between HSV-2 DNA load and HIV-1 DNA,
HIV-1 RNA load or the number of synonymous or non-
synonymous mutations in group 1 could be found (Spearman
rank correlation test, data not shown).
Finally, correlations between dS and dN of HIV-1 DNA or
RNA variants and HIV-1 RNA or HIV-1 DNA loads were
assessed in both genital secretions and blood, in order to
evaluate whether the number of substitutions could be related
to the level of HDV-2 genital replication.
No correlations were found between dS or dN and genital
HIV-1 DNA or HIV-1 RNA levels (dS, p 0.53 and r 0.22, and p
0.85 and r = 0.06, respectively; dN, p 0.34 and r = 0.33, and p
0.89 and r = 0.04, respectively; Spearman rank correlation test),
whereas plasma HIV-1 RNA levels correlated with both dS and
dN (p 0.017 and r = 0.62, and p 0.03 and r = 0.58, respectively).
Thus, the genetic diversity in plasma was associated with the
level of HIV-1 replication in blood, but not with the level of
replication in genital secretions.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectDiscussionThe aim of the present study was to evaluate whether HSV-2
genital reactivation may inﬂuence the genital replication and
diversity of HIV-1 in chronically HIV-1/HSV-2-co-infected
women. Two groups of HIV-1-infected women suffering from
genital ulcers and included in the ANRS12-12 trial were
compared, including those with HSV-2 genital replication
proven by real-time RT-PCR, and those with no HSV-2 genital
shedding, chosen as controls.
The group of women with evidence of HSV-2 genital shed-
ding had higher genital HIV-1 RNA loads than control women,
in agreement with other reports [8,10]. Compartmentalization
was observed between genital HIV-1 RNA, genital HIV-1 DNA,
and plasma HIV-1 RNA, independently of HSV-2 genital reac-
tivation, suggesting that HSV-2 genital replication did not
signiﬁcantly affect the tissue adaptation of HIV-1 variants.
Finally, we observed that HSV-2 genital replication was asso-
ciated with increased genetic diversity in cell-associated genital
HIV-1 variants (i.e. HIV-1 DNA) independently of genital HIV-1
DNA levels, but not in genital cell-free HIV-1 particles (i.e. HIV-
1 RNA).
Our ﬁndings indicate that HSV-2 genital replication may
modulate the variability of HIV-1 at the genital level in addition
to its inﬂuence on genital HIV-1 load and on the recruitment of
HIV-1 target cells at the mucosal level. Unexpectedly, no impact
was observed on the diversity of genital HIV-1 RNA. Indeed, a
previous study showed that the compartmentalization of HIV-1
RNA between the genital tract and blood may be observed in
cross-sectional analysis, probably because of a dynamicious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 873.e1–873.e9
FIG. 3. Numbers of synonymous sub-
stitutions per potential synonymous site
(dS) (circles), non-synonymous sub-
stitutions per potential non-synonymous
site (dN) (triangles) and dS/dN ratios
(squares) in genital human immunodeﬁ-
ciency virus (HIV)-1 DNA and RNA, and
in plasma HIV-1 RNA, for HIV-1 herpes
simplex virus type 2 (HSV-2)-co-infected
women with (group 1; bold) or without
(group 2; open) HSV-2 genital reac-
tivation. Mean dS and dN values of genital
HIV-1 DNA were higher in patients from
group 1 than in patients from group 2 by
the non-parametric Mann–Whitney U-
test. The dS/dN ratio of genital HIV-1
DNA showed a tendency to be higher
in patients from group 1 than in patients
from group 2, but the difference was only
at the limit of signiﬁcance (p 0.056). dS
and dN are expressed as percentages.
For each distribution, the median and
interquartile ranges are indicated.
CMI LeGoff et al. HIV-1 variability during HSV-2 infection 873.e7interchange of HIV-1 variants between the female genital tract
and blood [4]. Thus, one may hypothesize that the HIV-1 var-
iants that have migrated from the blood into the genital tract
viral population may mask the impact of HSV-2 genital repli-
cation on genital HIV-1 RNA diversity. The impact of HSV-2
genital shedding on the genetic diversity of HIV-1 DNA is
consistent with the results of a recent study using ex vivo human
exocervical tissue models, which showed greater levels of HIV-
1 DNA integration in HIV-1/HSV-2-co-infected tissues than in
tissues infected by HIV-1 only [30]. The mechanisms by which
HSV-2 genital replication may modulate HIV-1 genetic diversity
remain to be elucidated. APOBEC3 cellular proteins induce G-
to-A hypermutation in GG/GA dinucleotide contexts in HIV-1
DNA. The innate immune response triggered by HSV-2 genital
infection involves Toll-like receptors, plasmacytoid dendritic
cells, and type I interferons, all of which are known to induce
APOBEC3 expression [31]. Our results, however, did notClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inprovide any evidence for increased genital HIV-1 DNA diversity
related to G-to-A hypermutation.
The modulation of HIV-1 diversity within its genital cell-
associated reservoir occurred without basically changing the
fundamental phenotypic properties of the virus regarding the
predominance of synonymous changes, at least at the envelopw
level in the V1–V3 env region. Analysis of longer stretches
would be of interest, to determine whether the modulation of
genetic diversity may occur in other regions, such as those
coding for reverse transcriptase and protease genes. HSV-2 and
HIV-1 genital shedding may persist despite the use of antire-
troviral therapy. In particular, antiretroviral therapy was shown
to be ineffective in purging the female genital tract of cell-
associated provirus, and HSV-2 has been shown to decrease
the anti-HIV-1 activity of low doses of tenofovir in exocervical
tissue models [30]. Finally, the inﬂuence of HSV-2 genital
replication on reverse transcriptase and protease gene diversityfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 873.e1–873.e9
873.e8 Clinical Microbiology and Infection, Volume 21 Number 9, September 2015 CMIis likely to facilitate the selection of HIV-1 variants that are
resistant to antiretroviral drugs in cases of selective pressure.
Limitations of our study include the small size of the popu-
lation analysed, which may have impeded the detection of the
impact of HSV-2 genital shedding on genital HIV-1 RNA di-
versity. Furthermore, some samples had low copy numbers,
especially for HIV-1 DNA, which could represent a risk of
resampling bias. However, to deal with this limitation, we
removed identical clones. Identical results were nevertheless
observed when redundant sequences were included in the
analysis (data not shown).
In conclusion, our results show that HSV-2 genital reac-
tivation probably modulates HIV-1 genetic diversity at the
genital tract level. They conﬁrm the bilateral interactions be-
tween HSV-2 and HIV-1 at the genital level, and emphasize the
need to consider the control of HSV-2 replication for sustained
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